Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.20 USD

4.20
1,066,402

+0.25 (6.33%)

Updated Nov 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Ironwood to Halt MD-7246 Development After Study Failure

by Zacks Equity Research

Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.

Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.

Ironwood Pharmaceuticals (IRWD) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -63.64% and -7.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Ironwood (IRWD) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.

Ironwood (IRWD) Beats Earnings & Revenues Estimates in Q4

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) reports higher-than-expected earnings and revenues in the fourth quarter.

What's in Store for Ironwood (IRWD) This Earnings Season?

by Zacks Equity Research

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 Reasons Why Ironwood Stock Should Be in Your Portfolio

by Zacks Equity Research

We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.

MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%

by Zacks Equity Research

MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great Choice

by Zacks Equity Research

Does Ironwood Pharmaceuticals (IRWD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.

Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (IRWD) Outperforming Other Medical Stocks This Year?

Moving Average Crossover Alert: Ironwood Pharmaceuticals

by Zacks Equity Research

Ironwood Pharmaceuticals, Inc. (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Pacira's Late-Stage Study on Exparel Label Expansion Positive

by Zacks Equity Research

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

by Zacks Equity Research

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

by Zacks Equity Research

Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher

by Zacks Equity Research

Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.

Top Ranked Momentum Stocks to Buy for December 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd

Catalyst Focuses on Firdapse Label Expansion Amid Competition

by Zacks Equity Research

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics

Nalak Das headshot

5 Best-Performing, Top-Ranked Growth Stocks of November

by Nalak Das

Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.